{"id":"rifampin-containing-regimen","safety":{"commonSideEffects":[{"rate":"null","effect":"Hepatotoxicity"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Hemolysis"}]},"_chembl":{"chemblId":"CHEMBL374478","moleculeType":"Small molecule","molecularWeight":"822.95"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This inhibition prevents the transcription of essential bacterial genes, ultimately leading to the death of the bacteria. Rifampin is a broad-spectrum antibiotic that is effective against a wide range of bacteria, including Mycobacterium tuberculosis.","oneSentence":"Rifampin inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:12.016Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis"},{"name":"Prophylaxis of Mycobacterium tuberculosis infection"}]},"trialDetails":[{"nctId":"NCT07209761","phase":"PHASE3","title":"A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2025-10-16","conditions":"Pulmonary Tuberculosis","enrollment":532},{"nctId":"NCT07303699","phase":"PHASE2","title":"ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)","status":"RECRUITING","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2026-01-03","conditions":"Pulmonary Tuberculosis (TB)","enrollment":80},{"nctId":"NCT07345325","phase":"PHASE3","title":"Rifampin-free Regimen Versus Rifampin-containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditis","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-01","conditions":"Infective Endocarditis","enrollment":422},{"nctId":"NCT06585020","phase":"PHASE2","title":"Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2024-10-20","conditions":"Mycobacterium; Xenopi, Lung Diseases","enrollment":190},{"nctId":"NCT04734652","phase":"PHASE2","title":"INSTI's For The Management of HIV-associated TB","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2022-02-18","conditions":"HIV/AIDS, Tuberculosis, Pulmonary","enrollment":122},{"nctId":"NCT07191834","phase":"","title":"A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-30","conditions":"Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis, Type 2 Diabetes Mellitus (T2DM), Pretomanid","enrollment":60},{"nctId":"NCT06199921","phase":"PHASE2","title":"ATORvastatin in Pulmonary TUBerculosis","status":"RECRUITING","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2024-01-03","conditions":"Pulmonary Tuberculosis, Tuberculosis, Koch's Disease","enrollment":440},{"nctId":"NCT02563327","phase":"PHASE3","title":"Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-05-30","conditions":"Tuberculosis","enrollment":53},{"nctId":"NCT04311502","phase":"PHASE2","title":"Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-05","conditions":"HIV, Tuberculosis","enrollment":104},{"nctId":"NCT06917495","phase":"PHASE2","title":"Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shandong University","startDate":"2025-04-05","conditions":"Mild Spinal Tuberculosis","enrollment":300},{"nctId":"NCT05081401","phase":"PHASE3","title":"Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2022-05-23","conditions":"Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis, Pre-XDR-TB","enrollment":1050},{"nctId":"NCT06081361","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2023-12-22","conditions":"Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","enrollment":186},{"nctId":"NCT05971602","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis","status":"TERMINATED","sponsor":"Gates Medical Research Institute","startDate":"2023-07-26","conditions":"Pulmonary Tuberculosis","enrollment":93},{"nctId":"NCT05005637","phase":"PHASE2","title":"The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis with Positive IGRA","status":"COMPLETED","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2021-08-27","conditions":"Tuberculous Uveitis","enrollment":78},{"nctId":"NCT02410772","phase":"PHASE3","title":"TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-01-25","conditions":"Tuberculosis","enrollment":2516},{"nctId":"NCT04121195","phase":"PHASE2, PHASE3","title":"Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2020-10-30","conditions":"HIV/AIDS, Tuberculosis","enrollment":26},{"nctId":"NCT05169554","phase":"PHASE2","title":"Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy","status":"RECRUITING","sponsor":"Fundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID)","startDate":"2021-12-01","conditions":"Buruli Ulcer","enrollment":140},{"nctId":"NCT05047055","phase":"","title":"Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2022-03-15","conditions":"Tuberculosis, Pulmonary","enrollment":550},{"nctId":"NCT03678688","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-10-18","conditions":"Pulmonary TB","enrollment":122},{"nctId":"NCT03537495","phase":"PHASE2","title":"Pharmacokinetic Study of Linezolid for TB Meningitis","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2021-06-21","conditions":"Tuberculosis, Meningeal, Linezolid","enrollment":36},{"nctId":"NCT04050449","phase":"","title":"Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2019-10-28","conditions":"HIV-1-infection","enrollment":1339},{"nctId":"NCT02256696","phase":"PHASE2","title":"Assessing PA-824 for Tuberculosis (the APT Trial)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2015-04-29","conditions":"Pulmonary Tuberculosis","enrollment":157},{"nctId":"NCT05454345","phase":"PHASE3","title":"Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-10-01","conditions":"Tuberculosis, Pulmonary","enrollment":620},{"nctId":"NCT01751568","phase":"PHASE1, PHASE2","title":"Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-11-12","conditions":"HIV Infections, Tuberculosis","enrollment":40},{"nctId":"NCT00802802","phase":"PHASE1","title":"Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-02-10","conditions":"HIV Infections, Tuberculosis","enrollment":67},{"nctId":"NCT02178592","phase":"PHASE3","title":"Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-01-23","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":113},{"nctId":"NCT02114684","phase":"PHASE1, PHASE2","title":"Improving Retreatment Success (IMPRESS)","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2013-11","conditions":"Recurrent Tuberculosis","enrollment":197},{"nctId":"NCT00598897","phase":"PHASE4","title":"Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at Tyler","startDate":"1995-08","conditions":"Mycobacterium Avium Complex Lung Disease","enrollment":89},{"nctId":"NCT00598962","phase":"PHASE4","title":"Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at Tyler","startDate":"1994-12","conditions":"Mycobacterium Avium Complex","enrollment":58},{"nctId":"NCT00864383","phase":"PHASE3","title":"Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2008-01","conditions":"Pulmonary Tuberculosis","enrollment":1931},{"nctId":"NCT00694629","phase":"PHASE2","title":"TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2008-12","conditions":"Pulmonary Tuberculosis","enrollment":865},{"nctId":"NCT01805258","phase":"PHASE3","title":"Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences","startDate":"2007-06","conditions":"HIV/TB Co-infection","enrollment":135}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rifampin containing regimen","genericName":"Rifampin containing regimen","companyName":"Nantes University Hospital","companyId":"nantes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifampin inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase. Used for Tuberculosis, Prophylaxis of Mycobacterium tuberculosis infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}